Elite Pharmaceuticals (ELTP) Side-Steps Bankruptcy Threat, Posts Yearly Revenue Increase

QualityStocks would like to highlight Elite Pharmaceuticals, Inc. (OTCBB: ELTP). The company develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry.

In the company’s news yesterday,

Elite Pharmaceuticals announced results for the fiscal year ended March 31, 2011.

Total revenues increased 28 percent to $4.3 million compared to 2010 total revenues of $3.3 million. The company generated $1.6 million in positive cash flow, compared with negative operating cash flows of $1.4 million last year.

Elite attributes the increases primarily to the manufacture, sale and lab services related to its Lodrane line of products, which were discontinued in April 2011 after the U.S. Food and Drug Administration ordered the removal of hundreds of cough and cold and allergy products, including Lodrane, off the market.

The company reported a loss from operations at $0.9 million for the 2011 fiscal year, compared with a loss from operations of $1.9 million in the prior year.

Elite notes that the operating loss this fiscal year includes $1.4 million in charges stemming from a recent decision by the FDA, which the company said would have a significant negative impact on the company. Elite is appealing these decisions.

GAAP net loss for fiscal 2011 was $13.6 million, or $(0.14) per common share, compared to a GAAP net loss of $8.1 million, or a loss of $(0.11) in the prior year.

Jerry Treppel, chairman and CEO of Elite, emphasized the company’s successful efforts to stave off the threat of bankruptcy.

“I am extremely proud of all the employees at Elite who helped the company complete an astonishing operational turnaround from the verge of bankruptcy to an operating profit. Of course we cannot control the decision-making process of the FDA which has negated much of our hard work. Nonetheless, we have generated other revenue producing opportunities and will continue to do so,” Treppel stated in the press release.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.